Experience

Hello Group Acquires Happn

September 24, 2025

Cooley advised Hello Group, a leading player in Asia’s online social networking space, on its acquisition of Happn, a French location-based social search mobile and web application that enables users to connect with others based on their proximity and interests.

Read more

Related contacts

Yilin Xu
Partner, Beijing
Will Cai
Partner, Hong Kong
Ruomu Li
Partner, Shanghai
Michael Shen
Special Counsel, Shanghai
Lunga Su
Associate, Shanghai
Bartholomäus Regenhardt
Associate, Brussels
Patrick Van Eecke
Partner, Brussels
Charles Haley
Partner, Palo Alto
Xander Lee
Partner, Santa Monica
Hardy Zhou
Associate, New York
Athina Gaki
Associate, Brussels
Julie Paulino Montejo
Associate, New York
Len Jacoby
Partner, New York
Christopher Kimball
Partner, Washington, DC
John Paul Oleksiuk
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Dillon Martinson
Special Counsel, Washington, DC
Yi Jia Ng
Special Counsel, Singapore
Anna Caro
Associate, London
Michael Pelle
Associate, New York
Harvey Yao
Associate, Hong Kong
Veronica Cortes
Paralegal Specialist, New York

Related Practices & Industries

Ambiq Micro Announces Pricing of $96 Million IPO

July 30, 2025

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).

Read more

Related contacts

Christina T. Roupas
Partner in Charge – Chicago, Chicago
Courtney M.W. Tygesson
Partner, Chicago
Michael Platt
Partner in Charge – Colorado, Colorado
Kelly Bartling
Special Counsel, Colorado
Grady Chang
Associate, Santa Monica
Keith Berets
Partner, Colorado
Will Cai
Partner, Hong Kong
Annie Froehlich
Partner, Washington, DC
Austin Holt
Partner, Santa Monica
Len Jacoby
Partner, New York
Christopher Kimball
Partner, Washington, DC
Kevin King
Partner, Washington, DC
Patrick Loofbourrow
Partner, Singapore
Barbara Mirza
Partner, Santa Monica
Tim Pitrelli
Partner, Singapore
Nicola Squire
Partner, London
Jeffrey J. Tolin
Partner, New York
Francis Wheeler
Senior Counsel, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Alaina DeBona
Special Counsel, Chicago
Andrew Epstein
Special Counsel, Seattle
Brooke Fritz
Special Counsel, Colorado
Rebecca Ross
Special Counsel, Washington, DC
Vince Sampson
Special Counsel, Washington, DC
Michael Shen
Special Counsel, Shanghai
Karen Tsai
Special Counsel, Washington, DC
Blake Martell
Of counsel, San Francisco
Mateus Kaba Aboud
Associate, Chicago
Adam Bloom
Associate, Chicago
Umer Chaudhry
Associate, Washington, DC
Stefan Cohen
Associate, New York
Megan Drill
Associate, San Diego
Ryan Guo
Associate, New York
Sarah Oliai
Associate, Washington, DC
Samuel Paullin
Associate, Chicago
Taryn Wilkins
Associate, Chicago
Katherine Duplay
Paralegal Specialist, Colorado
Alla Kagan
Paralegal Specialist, San Diego
Robin K. Lee
Paralegal Specialist, Colorado
Brian Youn
Paralegal Specialist, Palo Alto
Brian Mitchell
Transactional Quantitative Analyst, San Diego

Related Practices & Industries

InnoCare and KeyMed Jointly Announce License Agreement With Prolium

January 20, 2025

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Michael Shen
Special Counsel, Shanghai
Ivy Wang
Associate, Shanghai
Letian Wei
Legal Consultant, Shanghai
Jameson Davis
Associate, Boston
Robert Eisenbach
Of Counsel, San Francisco
Xander Lee
Partner, Santa Monica
Bin Wang
Special Counsel, Palo Alto
Monica Xu
Special Counsel, Shanghai

Related Practices & Industries

Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement

November 18, 2024

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Read more

Related contacts

Mark Ballantyne
Partner, Reston
Kenneth Krisko
Partner, Reston
J. Brian Stalter
Special Counsel, New York
Ruomu Li
Partner, Shanghai
David Brinton
Associate, Washington, DC
Arjan Ganji
Associate, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Daniel I. Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Francis Wheeler
Senior Counsel, Colorado
Rebecca Ross
Special Counsel, Washington, DC
John Forrest
Associate, Boston
Zack Gong
Associate, Shanghai
Michael Shen
Special Counsel, Shanghai
Robin K. Lee
Paralegal Specialist, Colorado

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Out-Licenses GLP-1 Portfolio

May 17, 2024

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Read more

Related contacts

Sharon Connaughton
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Zack Gong
Associate, Shanghai
Kevin King
Partner, Washington, DC
Edmond Lay
Partner, San Diego
Howard Morse
Senior Counsel, Washington, DC
Sarah Oliai
Associate, Washington, DC
W. Chad Shear
Partner, San Diego
Michael Shen
Special Counsel, Shanghai
Alan W. Tamarelli
Partner, New York
Karen Tsai
Special Counsel, Washington, DC
Ivy Wang
Associate, Shanghai
Bin Wang
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Joanna Zhang
Associate, San Diego

Related Practices & Industries

View more

Admissions and credentials

New York

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.